Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Studies in rodents have implicated various cytokines as paracrine mediators of increased osteoclastogenesis during estrogen deficiency, but increases in RANKL, the final effector of osteoclastogenesis, have not been demonstrated. Thus, we isolated bone marrow mononuclear cells expressing RANKL on their surfaces by two-color flow cytometry using FITC-conjugated osteoprotegerin-Fc (OPG-Fc-FITC) as a probe. The cells were characterized as preosteoblastic marrow stromal cells (MSCs), T lymphocytes, or B lymphocytes by using Ab's against bone alkaline phosphatase (BAP), CD3, and CD20, respectively, in 12 premenopausal women (Group A), 12 early postmenopausal women (Group B), and 12 age-matched, estrogen-treated postmenopausal women (Group C). Fluorescence intensity of OPG-Fc-FITC, an index of the surface concentration of RANKL per cell, was increased in Group B over Groups A and C by two- to threefold for MSCs, T cells, B cells, and total RANKL-expressing cells. Moreover, in the merged groups, RANKL expression per cell correlated directly with the bone resorption markers, serum C-terminal telopeptide of type I collagen and urine N-telopeptide of type I collagen, in all three cell types and inversely with serum 17beta-estradiol for total RANKL-expressing cells. The data suggest that upregulation of RANKL on bone marrow cells is an important determinant of increased bone resorption induced by estrogen deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, estrogen deficiency is associated with an expansion of RANKL-and TNF-expressing T cells and B cells (27,28,30,31).”
From Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics (2016) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“RANKL levels were increased on the surface of bone marrow cells from early postmenopausal women who are estrogen deficient”
From Pathogenesis of osteoporosis: concepts, conflicts, and prospects (2005) · cites this paper as [48]
In the citing paper
“Moreover, estrogen stimulates these bone cells to produce osteoprotegerin (OPG), a decoy receptor of RANK in osteoclast, thus inhibiting osteoclastogenesis [19, 155–159].”
From Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells (2015) · cites this paper as [157]
In the citing paper
“In humans, estrogen deficiency is associated with increased RANKL expression by bone marrow osteoblastic, T and B cells, whereas estrogen treatment reversed this increase ( 76).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [76]
In the citing paper
“flow cytometry studies conducted with bone marrow aspirates from postmenopausal subjects showed that saturating levels of OPG did not reduce the ability of anti-TRAIL antibodies to recognize TRAIL-positive cells (76).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [76]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“The expression of RANKL by T cells may be related, in part, to their function as immunoregulators, because targeted disruption of the RANKL gene results in mice lacking lymph nodes and with defective T and B lymphocyte differentiation (45).”
BackgroundSelf-citationManolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,568
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471 · cited 1×
“For example, ERα knockout mice have short limbs and mild osteopenia (31), whereas a young adult male with homozygous null mutations of ERα had elongated limbs and a greater degree of osteopenia (32).”
BackgroundSuda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0367 · Cited by 2,336
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
Couse, J. F., & Korach, K. S. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0370 · Cited by 2,045
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856 · cited 1×
“In an experimental mouse model of inflammatory arthritis, activated T lymphocytes expressing RANKL were shown to regulate the associated periarticular bone loss and joint destruction (46).”
BackgroundSelf-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Self-citation
Research works printed but not linked: 8
- 10.1210/jc.87.4.1443 · doi:10.1210/jc.87.4.1443 · Paper page
- 10.1210/en.142.12.5050 · doi:10.1210/en.142.12.5050 · Paper page
- 10.1210/en.140.9.4367 · doi:10.1210/en.140.9.4367 · Paper page
- 10.1210/en.142.6.2205 · doi:10.1210/en.142.6.2205 · Paper page
- 10.1210/jc.87.4.1550 · doi:10.1210/jc.87.4.1550 · Paper page
- 10.1210/en.141.12.4768 · doi:10.1210/en.141.12.4768 · Paper page
- Owen, 1988, Ciba Found. Symp., 136, 42
- 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6 · DOI
Cited by
Items 301–400 of 821
Chappard, D., Bouvard, B., Baslé, M. F., Legrand, É., & Audran, M. (2011) · Morphologie · doi:10.1016/j.morpho.2011.02.004 · Cited by 41
Passeri, E., Benedini, S., Costa, E., & Corbetta, S. (2015) · International Journal of Endocrinology · doi:10.1155/2015/352858 · Cited by 39
“Increased RANKL activity has been demonstrated in diseases characterized by excessive bone loss such as osteoporosis [2].”
BackgroundA Review on the Molecular Mechanisms of Action of Natural Products in Preventing Bone Diseases
Okagu, I. U., Ezeorba, T. P. C., Aguchem, R. N., Ohanenye, I. C., Aham, E. C., Okafor, S. N., Bollati, C., & Lammi, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158468 · Cited by 40
“Other evidence of the involvement of the immune system is represented by B-cells, which regulate the RANK/RANKL/OPG axis, and which increase the production of RANKL in postmenopausal women [53,54].”
BackgroundImmunoregulation of bone remodelling
Singh, A. K., Mehdi, A., Srivastava, R., & Verma, N. (2012) · International Journal of Critical Illness and Injury Science · doi:10.4103/2229-5151.97271 · Cited by 50
Society for endocrinology guideline for understanding, diagnosing and treating female hypogonadism
Jayasena, C. N., Devine, K., Barber, K., Comninos, A. N., Conway, G. S., Crown, A. L., Davies, M. C., Ewart, A., Seal, L., Smyth, A., et al. (2024) · Clinical Endocrinology · doi:10.1111/cen.15097 · Cited by 57
“…osteoclastic activity and subsequent bone resorption through a number of pathways in humans, including through tumour necrosis factor ‐ α (TNF ‐ α ), 203 interleukin ‐ 1 β (IL ‐ 1 β ), 203 receptor activator of nuclear factor κ B ligand (RANKL), 204 and sclerostin (Wnt signalling) pathways.”
Ismaila, M. S., Mahmud, R., Zakaria, Z. A. B., Imam, M. U., & Ismail, M. (2013) · Clinical Interventions in Aging · doi:10.2147/cia.s45943 · Cited by 37
“52–54 ORZ has been shown to have an upregulatory effect on antioxidant genes.”
RANKL inhibition for the management of patients with benign metabolic bone disorders
Anastasilakis, A. D., Toulis, K. A., Pοlyzos, S. A., & Terpos, E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903048929 · Cited by 39
“Finally, sRANKL constitutes only a small part of total RANKL, as the majority is cell-bound and thus not detectable in the circulation [26].”
BackgroundOh, S.-R., Kyung, T.-W., & Choi, H. (2008) · Molecules and Cells · doi:10.1016/s1016-8478(23)14027-1 · Cited by 52
Regulation of Bone Turnover by Sex Steroids in Men
Sanyal, A., Hoey, K. A., Mödder, U. I., Lamsam, J., McCready, L. K., Peterson, J. M., Achenbach, S. J., Oursler, M. J., & Khosla, S. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.071212 · Cited by 42
“We have previously shown that these cells express bone-related genes (ALP, osteocalcin, collagen I) and can form mineralized nodules in vitro.((9)) Because we wanted to be certain we had sufficient numbers of cells for the mRNA analyses, we did not perform a further round of purification by fluorescent activated cell…”
BackgroundMethodResultInfluentialSelf-citationInteractions of B-lymphocytes and bone cells in health and disease
Grčević, D., Sanjay, A., & Lorenzo, J. (2023) · Bone · doi:10.1016/j.bone.2021.116296 · Cited by 36
Clinical utility of denosumab for treatment of bone loss in men and women
Adler, R. A., & Gill, R. S. (2011) · Clinical Interventions in Aging · doi:10.2147/cia.s14565 · Cited by 40
Zhi, X., Wang, L., Chen, H., Fang, C., Cui, J., Hu, Y., Cao, L., Weng, W., Zhou, Q., Qin, L., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14790 · Cited by 39
Minireview: Nuclear Receptor Regulation of Osteoclast and Bone Remodeling
Jin, Z., Li, X., & Wan, Y. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1316 · Cited by 39
“Untreated early postmenopausal women are reported to exhibit elevated RANKL in bone marrow cells compared with estrogen-replete women (142).”
VURAL, P., Canbaz, M., & Akgül, C. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.01.005 · Cited by 40
Nabipour, I., Larijani, B. A., Vahdat, K., Assadi, M., Jafari, S. M., Ahmadi, E., Movahed, A., Moradhaseli, F., Sanjdideh, Z., Obeidi, N., et al. (2009) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181a181b8 · Cited by 41
Bharadwaj, S., Naidu, T. A. G., Betageri, G. V., Prasadarao, N. V., & Naidu, A. S. (2010) · Inflammation Research · doi:10.1007/s00011-010-0211-7 · Cited by 38
Shi, C., Wu, J., Yan, Q., Wang, R., & Miao, D. (2015) · Bone · doi:10.1016/j.bone.2015.05.034 · Cited by 37
“Previous studies in women and animal models of postmenopausal osteoporosis documented increases in both bone resorption and bone formation based on serum and urinary markers as well as direct histological assessment of bone turnover [36–39].”
ResultDrake, M. T., Srinivasan, B., Mödder, U. I., Ng, A. C., Undale, A. H., Roforth, M. M., Peterson, J. M., McCready, L. K., Riggs, B. L., & Khosla, S. (2011) · Bone · doi:10.1016/j.bone.2011.05.003 · Cited by 38
“In addition, we have also previously demonstrated that estrogen deficiency is associated with increased RANKL protein expression by bone marrow AP+ cells [8] and that serum bone resorption markers are correlated with RANKL expression by bone marrow lin-/AP+ cells [9].”
BackgroundSelf-citationCheng, L., Zhou, S., Zhao, Y., Sun, Y., Xu, Z. Q., Yuan, B., & Chen, X. (2018) · Europe PMC (PubMed Central) · Cited by 41
Molecular Aspects of Bone Remodeling
Alma, Y., Valdés‐Flores, M., Orozco, L., & Velzquez-Cruz, R. (2013) · InTech eBooks · doi:10.5772/54905 · Cited by 58
“Specifically, estrogen stimulates the expression of OPG in mouse osteo‐ blasts and stromal cells [94].”
BackgroundResultMicrodamage repair and remodeling requires mechanical loading
Waldorff, E. I., Christenson, K., Cooney, L. A., & Goldstein, S. A. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.091016 · Cited by 40
“For analysis of the flow cytometric data, the forward scatter and side scatter gate was set to a region that has been shown previously to include stem cells and monocytes.((35)) The CD117þ and CD11bþ populations within the gate were identified as cells expressing specific levels of fluorescent activity above the nonsp…”
MethodUemura, H., Yasui, T., Miyatani, Y., Yamada, M., Hiyoshi, M., Arisawa, K., & Irahara, M. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03345584 · Cited by 41
Molecular Mechanisms of the Biphasic Effects of Interferon-γ on Osteoclastogenesis
Cheng, J. Q., Liu, J., Shi, Z., Jules, J., Xu, D., Luo, S., Shi, W., & Feng, X. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0019 · Cited by 40
Bianchi, E. N., & Ferrari, S. (2009) · Bone · doi:10.1016/j.bone.2009.06.020 · Cited by 36
“Hence the in vivo regulation of RANKL (andothers) gene expressionbyβ-arrestin2maybe further influenced by the level of gonadal steroids [43].”
Parveen, B., Tiwari, A., Jain, M., Pal, S., Chattopadhyay, N., Tripathi, M., & Vohora, D. (2018) · Bone · doi:10.1016/j.bone.2018.05.011 · Cited by 35
Chen, B., Li, X., Liu, D., Wang, H., Xie, P., Liu, Z.-Y., Hou, G., Chang, B., & Du, S. (2012) · Phytomedicine · doi:10.1016/j.phymed.2012.06.002 · Cited by 36
“It has been shown that RANKL expression is elevated in bone marrow cells of postmenopausal women (Eghbali-Fatourechi et al. 2003).”
BackgroundOvariectomy increases RANKL protein expression in bone marrow adipocytes of C3H/HeJ mice
Beekman, K. M., Zwaagstra, M., Veldhuis‐Vlug, A. G., van Essen, H. W., den Heijer, M., Maas, M. M., Kerckhofs, G., Parac‐Vogt, T. N., Bisschop, P. H. L. T., & Bravenboer, N. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00142.2019 · Cited by 39
Jhong, J.-H., Tsai, W.-H., Yang, L.-C., Chou, C.-H., Lee, T.-Y., Yeh, Y., Huang, C., & Luo, Y.-H. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.804210 · Cited by 35
Blockade of CD26 Signaling Inhibits Human Osteoclast Development
Nishida, H., Suzuki, H., Madokoro, H., Hayashi, M., Morimoto, C., Sakamoto, M., & Yamada, T. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2277 · Cited by 36
Ohwada, R., Hotta, M., Sato, K., Shibasaki, T., & Takano, K. (2007) · Endocrine Journal · doi:10.1507/endocrj.k07-034 · Cited by 36
“It is reported that serum levels of RANKL and OPG increased in postmenopausal women [14, 15].”
BackgroundCarlo, C. D., Tommaselli, G. A., Gargano, V., Sammartino, A., Bifulco, G., Tauchmanovà, L., Colao, A., & Nappi, C. (2006) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000227855.04732.7b · Cited by 34
“Other studies have failed to confirm these data.(15,16)”
ResultThe effect of exercise and estrogen on osteoprotegerin in premenopausal women
West, S., Scheid, J. L., & Souza, M. J. D. (2008) · Bone · doi:10.1016/j.bone.2008.09.008 · Cited by 36
“OPG is proving to be important in the pathogenesis of bone loss in postmenopausal women [27,29–33] and underscores the importance of investigating this cytokine in a premenopausal cohort.”
BackgroundIguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways
Li, C., Ma, Z., Jian, L., Wang, X.-Y., Sun, L., Liu, X., Yao, Z., & Zhao, J. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107219 · Cited by 38
Kanadys, W. M., Barańska, A., Błaszczuk, A., Polz‐Dacewicz, M., Drop, B., Malm, M., & Kanecki, K. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105346 · Cited by 39
“Bone loss increases two years before menopause and is at its highest level during the first 3 years of menopause, with losses reaching 3–5% annually [15].”
BackgroundThe Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects
Lu, W., Xiao, W., Xie, W., Fu, X., Pan, L., Jin, H., Yu, Y., Zhang, Y., & Li, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.735374 · Cited by 36
“Increased levels of RANKL in menopausal women play a major role in the occurrence of osteoporosis, since the molecule can activate cell differentiation by binding to its receptor (RANK) and improves the activity and survival rate of osteoclasts (Eghbali-Fatourechi et al., 2003; Lacey et al., 2012).”
BackgroundOophorectomy‐induced bone loss is attenuated in MAGP1‐deficient mice
Craft, C. S., Broekelmann, T. J., Zou, W., Chappel, J. C., Teitelbaum, S. L., & Mecham, R. P. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23331 · Cited by 33
“Estrogen depletion, which occurs during menopause and following OVX, induces bone loss through the upregulation of RANKL [Eghbali-Fatourechi et al., 2003; Samadfam et al., 2007; Ominsky et al., 2008].”
BackgroundThe RANKL Pathway and Denosumab
Dore, R. K. (2011) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2011.07.004 · Cited by 38
“Postmenopausal women express higher levels of RANKL on marrow stromal cells or lymphocytes than premenopausal women or postmenopausal women taking estrogen.(6) RANKL expression is inversely correlated with serum levels of 17b-estradiol and positively correlated with levels of bone resorption markers.”
BackgroundDenosumab: an investigational drug for the management of postmenopausal osteoporosis
Lewiecki, M. E. (2008) · Biologics · doi:10.2147/btt.s2082 · Cited by 37
“Flow cytometry of bone marrow cells of pre- and postmenopausal women showed upregulation of RANKL after menopause (Eghbali-Fatourechi et al 2003), consistent with RANKL playing a role in high bone turnover and bone loss commonly associated with this population.”
ResultMaternal plasma osteoprotegerin concentration in normal pregnancy
Hong, J., Santolaya-Forgas, J., Romero, R. J., Espinoza, J., Gonçalves, L. F., Kim, Y. M., Edwin, S. S., Yoon, B. H., Nien, J. K., Hassan, S. S., et al. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.06.051 · Cited by 37
Narducci, P., Bareggi, R., & Nicolin, V. (2009) · Acta Histochemica · doi:10.1016/j.acthis.2009.10.003 · Cited by 38
“Recent studies have shown that the upregula- tion of RANKL on bone marrow cells induced by estrogen deficiency in postmenopausal women is responsible for the bone resorption (Eghbali-Fatourechi et al., 2003).”
BackgroundThe Epidemiology and Pathogenesis of Osteoporosis
Rosen, C. J. (2014) · Europe PMC (PubMed Central) · Cited by 38
Exosomes as a Novel Approach to Reverse Osteoporosis: A Review of the Literature
Xie, X., Xiong, Y., Panayi, A. C., Hu, L., Zhou, W., Xue, H., Lin, Z., Chen, L., Yan, C., Mi, B., et al. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.594247 · Cited by 35
Das, A. S., Mukherjee, M., Das, D., & Mitra, C. (2009) · Phytotherapy Research · doi:10.1002/ptr.2719 · Cited by 33
“RANKL is known as a highly potent, final effector of osteoclast formation and function and subsequent bone loss in estrogen deficient condition (Eghbali-Fatourechi et al., 2003).”
Iolascon, G., Napolano, R., Gioia, M., Moretti, A., Riccio, I., & Gimigliano, F. (2013) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2013.10.1.047 · Cited by 47
The unbearable lightness of bone marrow homeostasis
Agas, D., Marchetti, L., Douni, E. K., & Sabbieti, M. G. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.12.004 · Cited by 33
“On the other hand, when RANKL overwhelms the effects of OPG, as occurs in RANKL transgenic mice [100] and in postmenopausal osteoporosis [101], the imbalance in bone remodelling results in bone resorption.”
BackgroundAlterations in the phenotype and function of immune cells in ovariectomy-induced osteopenic mice
García‐Pérez, M. Á., Noguera, I., Hermenegildo, C., Martínez‐Romero, A., Tarín, J. J., & Cano, A. (2006) · Human Reproduction · doi:10.1093/humrep/dei413 · Cited by 31
“In accordance with our data, after ovariectomy, decreases have been described in the percentage of preosteoblastic marrow stromal cells in early postmenopausal women (Eghbali-Fatourechi et al., 2003), in serum ALP activity (Sakakura et al.”
BackgroundMethodBone loss goes beyond estrogen
Martin, T. J., & Gaddy, D. (2006) · Nature Medicine · doi:10.1038/nm0606-612 · Cited by 33
Glucocorticoids in Patients with Rheumatic Diseases: Friends or Enemies of Bone?
Ciccarelli, F., Martinis, M. D., & Ginaldi, L. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106125051 · Cited by 38
“it cross-talk between bone-resorbing osteoclasts and boneforming osteoblasts [3].”
BackgroundProteomics Profiling of Osteoporosis and Osteopenia Patients and Associated Network Analysis
Al‐Ansari, M. M., Aleidi, S. M., Masood, A., Alnehmi, E. A., Jabar, M. A., Mogren, M. A., Alshaker, M., Benabdelkamel, H., & Rahman, A. M. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710200 · Cited by 37
“Mature B cells not only synthesize Ig, but they also secrete signaling molecules (such as receptor activators of nuclear factor-kappa κB ligand (RANKL) and osteoprotegerin (OPG) that regulate bone homeostasis through their actions on osteoblasts and osteoclasts [33,34].”
BackgroundLee, H., Finkelstein, J. S., Miller, M. E., Comeaux, S. J., Cohen, R., & Leder, B. Z. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2495 · Cited by 32
Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease
Yuan, Y. Y., Kostenuik, P. J., Ominsky, M. S., Morony, S., Adamu, S., Simionescu, D. T., Basalyga, D. M., Asuncion, F., & Bateman, T. A. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0509-7 · Cited by 33
“RANKL is a member of TNF superfamily that is expressed by osteoblasts [8], bone marrow stromal cells [9], and activated T-cells [10].”
BackgroundInfluentialWang, Y., Chen, J., Luo, X., Zhang, Y., Si, M., Wu, H., Chang, Y., & Wei, W. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.12.019 · Cited by 33
Cell biology of osteoimmunology
Gruber, R. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0809-y · Cited by 31
“RANKL is also increased in marrow T-cells (but also in B-cells and monocytes) of women with postmenopausal osteoporosis [41].”
BackgroundBrüggmann, D., Mäule, L.-S., Klingelhöfer, D., Schöffel, N., Gerber, A., Jaque, J. M., & Groneberg, D. A. (2016) · Climacteric · doi:10.1080/13697137.2016.1200548 · Cited by 32
Hu, B., Sun, X., Yang, Y., Ying, Z., Meng, J., Zhou, C., Jiang, G., Li, S., Wu, F., Zhao, X., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201800920r · Cited by 30
“Overactivation of osteoclastogenesis leading to excessive bone loss is amajor component of the pathogenesis of postmenopausal osteoporosis (41).”
BackgroundGeoghegan, I. P., McNamara, L. M., & Hoey, D. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-88633-6 · Cited by 35
Glycosaminoglycans modulate RANKL‐induced osteoclastogenesis
Ling, L., Murali, S., Stein, G. S., van Wijnen, A. J., & Cool, S. M. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22506 · Cited by 31
Treatment of beta‐thalassaemia‐associated osteoporosis with zoledronic acid
Perifanis, V., Vyzantiadis, T., Vakalopoulou, S., Τζιόμαλος, Κ., Garypidou, V., Athanassiou‐Metaxa, M., & Harsoulis, F. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04871.x · Cited by 29
Impact of aromatase inhibitors on bone health in breast cancer patients
Geisler, J., & Lønning, P. E. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.10.004 · Cited by 31
Jilka, R. L., Bellido, T., Almeida, M., Plotkin, L. I., O’Brien, C. A., Weinstein, R. S., & Manolagas, S. C. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00032-x · Cited by 37
Lim, Y. W., Chun, S. H., Lee, J. H., Baek, K., Lee, W. K., Yim, H. W., & Kang, M. I. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3527-5 · Cited by 31
Ferreira, E. C. S., Bortolin, R. H., Freire‐Neto, F. P., de Souza, K. S. C., Bezerra, J. F., Ururahy, M. A. G., Ramos, A. M. D. O., Himelfarb, S. T., Abreu, B. J., Didone, T. V. N., et al. (2017) · Nutrition Research · doi:10.1016/j.nutres.2017.03.004 · Cited by 30
Park, B., Song, H. S., Kwon, J. E., Cho, S. M., Jang, S., Kim, M. Y., & Kang, S. C. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-2047-y · Cited by 31
“Additionally, it is critical in the occurrence of postmenopausal bone loss [70].”
BackgroundA practical guide to the diagnosis and management of osteoporosis in childhood and adolescence
Ward, L. M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1266986 · Cited by 38
Air Pollutants Interaction and Gender Difference on Bone Mineral Density T-Score in Taiwanese Adults
Lin, Y., Wang, C.-F., Chiu, H., Lai, B.-C., Tu, H., Wu, P.-Y., Huang, J., & Chen, S. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17249165 · Cited by 30
“Estrogen regulates RANKL, and this is mediated by the production of cytokines such as IL-1, IL-6, and TNF [52].”
BackgroundInfluentialB cell autoimmunity and bone damage in rheumatoid arthritis
Bugatti, S., Bogliolo, L., Montecucco, C., & Manzo, A. (2016) · Reumatismo · doi:10.4081/reumatismo.2016.914 · Cited by 29
“women not on estrogen replacement (41),”
Pathophysiology of Osteoporosis
Rodan, G. A., Raisz, L. G., & Bilezikian, J. P. (2002) · Elsevier eBooks · doi:10.1016/b978-012098652-1.50175-x · Cited by 37
The immune system and postmenopausal osteoporosis
D’Amelio, P. (2013) · Immunological Investigations · doi:10.3109/08820139.2013.822764 · Cited by 30
“The unbalance between RANKL and OPG has been indicated as the pivotal mechanism responsible for estrogen deficiency bone loss (Eghbali-Fatourechi et al., 2003; Hofbauer et al., 2000).”
The Effects of Tualang Honey on Bone Metabolism of Postmenopausal Women
Effendy, N. M., Mohamed, N., Muhammad, N., Naina-Mohamed, I., & Shuid, A. N. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/938574 · Cited by 36
“Upregulation of osteoclastogenesis occurs via activation of receptor activator of nuclear factor kappaB ligand (RANKL) [39] and diminishes production of osteoprotegerin (OPG), which function as osteoclastogenesis inhibitory factor [40].”
BackgroundMandibular Gorham–Stout disease
Liu, M., Liu, W., Qiao, C., & Han, B. (2017) · Medicine · doi:10.1097/md.0000000000008184 · Cited by 26
“Some researchers have also proposed involvement by the RANKligand/RANK system,([4]) and a variety of bone diseases such as postmenopausal osteoporosis([5]) and inflammatory bone loss.”
BackgroundClinical applications of RANK‐ligand inhibition
Romas, E. (2009) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2008.01732.x · Cited by 31
Prevention of Trabecular Bone Loss Induced by Estrogen Deficiency by a Selective p38α Inhibitor
Caverzasio, J., Higgins, L. S., & Ammann, P. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080410 · Cited by 35
“Various cytokines such as RANKL,((4)) TNF , IFN ,((5)) IL-7,((32)) and IL-1((6)) have been suggested to play a role in enhanced osteoclastogenesis with estrogen deficiency.”
BackgroundInfluentialRachner, T. D., Schoppet, M., Niebergall, U., & Hofbauer, L. C. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.01.118 · Cited by 29
Anastasilakis, A. D., Goulis, D. G., Pοlyzos, S. A., Gerou, S., Pavlidou, V., KOUKOULIS, G. N., & Avramidis, A. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0528 · Cited by 29
“Cell surface production of RANKL can be assessed in vivo in humans by flow cytometry ( 25 ), an impractical method that usually requires bone biopsy; even if performed in peripheral blood, local (i.e., bone marrow) production of RANKL is probably the most relevant.”
BackgroundPulsatelli, L., Dolzani, P., Silvestri, T., Caraceni, P., Facchini, A., Ravaglia, G., Salvarani, C., Melicòni, R., & Mariani, E. (2004) · Biogerontology · doi:10.1023/b:bgen.0000025075.04136.ec · Cited by 29
“Furthermore, our results are also supported by other studies that reported no relationship between estrogen and serum concentrations of OPG (Khosla et al. 2002) and RANKL ( Eghbali-Fatourechi et al. 2003 ).”
BackgroundResultInfluentialLucateli, R. L., Silva, P. H. F., Salvador, S. L. D. S., Ervolino, E., Furlaneto, F. A. C., Marciano, M. A., Antunes, T. B. M., Arco, M. C. G. D., Tardelli, M. D. C., de Sousa, L. G., et al. (2024) · Journal of Periodontal Research · doi:10.1111/jre.13256 · Cited by 29
Bone marrow adipogenic lineage precursors are the major regulator of bone resorption in adult mice
Lu, J., He, Q., Wang, H., Yao, L., Duffy, M. P., Guo, H., Braun, C., Zhou, Y., Liang, Q., Lin, Y., et al. (2025) · Bone Research · doi:10.1038/s41413-025-00405-4 · Cited by 29
Bone mass regulation of leptin and postmenopausal osteoporosis with obesity.
Siswo, L., & Brandi, M. L. (2012) · Europe PMC (PubMed Central) · Cited by 34
Dudeck, J., Rehberg, S., Bernhardt, R., Schneiders, W., Zierau, O., Manjubala, I., Goebbels, J., Vollmer, G., Fratzl, P., Scharnweber, D., et al. (2014) · Acta Biomaterialia · doi:10.1016/j.actbio.2014.01.034 · Cited by 26
Ke, D., Yu, Y., Li, C., Han, J., & Xu, J. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00449-w · Cited by 29
Osteoimmunopathology in HIV/AIDS: A Translational Evidence-Based Perspective
Barkhordarian, A., Ajaj, R. A., Ramchandani, M. H., Demerjian, G. G., Cayabyab, R., Danaie, S., Ghodousi, N., Iyer, N., Mahanian, N., Phi, L., et al. (2011) · Pathology Research International · doi:10.4061/2011/359242 · Cited by 26
“Therefore, production of OPGL by osteoblast lineage cells and activated T cells can directly regulate osteoclastogenesis and bone remodeling [14, 15].”
BackgroundHe, J., Yang, L., Qing, Y., & He, C. (2013) · Acupuncture in Medicine · doi:10.1136/acupmed-2012-010271 · Cited by 24
Carvalho, M. D., Benatti, B. B., Neto, J. B. C., Nociti, F. H., Filho, G. D. R. N., Casati, M. Z., & Sallum, E. A. (2006) · Journal of Periodontology · doi:10.1902/jop.2006.050190 · Cited by 34
Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis
Thulin, M. H., Nilsson, M., Thulin, P., Céraline, J., Ohlsson, C., Damber, J., & Welén, K. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.11.013 · Cited by 27
Bone abnormalities in young male rats with iron intervention and possible mechanisms
Li, Y., Bai, B., & Zhang, Y. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.11.005 · Cited by 25
Parathyroid Diseases and T Cells
Weitzmann, M. N., & Pacifici, R. (2017) · Current Osteoporosis Reports · doi:10.1007/s11914-017-0359-y · Cited by 28
Estrogen Receptor Agonists and Immune System in Ovariectomized Mice
Garcí-Pérez, M. A., del Val, R., Noguera, I., Hermenegildo, C., Pineda, B., Martínez‐Romero, A., & Cano, A. (2006) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200601900410 · Cited by 27
“In agreement with our data, decreases in serum ALP and in pre-osteoblastic cells in estrogen deficiency (18), and a down-regulation of ALP and Cbfal gene expression by ovariectomy and an upregulation by estrogens in BM mesenchymal stem cells of mice (19), have been described.”
ResultInfluentialThe gut microbiota in osteoporosis: dual roles and therapeutic prospects
Xie, X., Liu, H., Wan, K., Li, J., & Qi, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1617459 · Cited by 26
Ikeda, K., Tsukui, T., Horie‐Inoue, K., & Inoue, S. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.038 · Cited by 26
“It has been suggested that estrogen suppresses RANKL production [9] and increases OPG production [10] by osteoblastic cells.”
Qiao, S., Zhang, X., Chen, Z., Zhao, Y., & Tzeng, C. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110954 · Cited by 25
Khosla, S. (2010) · Translational endocrinology & metabolism · doi:10.1210/team.9781879225718.ch2 · Cited by 27
“Combined in vitro and in vivo studies have now demonstrated that estrogen suppresses RANKL production by osteoblastic, T- and B-cells (73) and also increases OPG production (76, 77).”
BackgroundSelf-citationNovel therapies in benign and malignant bone diseases
Rachner, T. D., Hadji, P., & Hofbauer, L. C. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.02.005 · Cited by 25
“Vice versa, bone protective substances such as estrogens are known to suppress RANKL and enhance OPG (Eghbali-Fatourechi et al., 2003).”
BackgroundMartin, A., Yu, J., Xiong, J., Khalid, A. B., Katzenellenbogen, B. S., Kim, S. H., Katzenellenbogen, J. A., Malaivijitnond, S., Gabet, Y., Krum, S. A., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25862 · Cited by 25
“Clinical relevance of our work is suggested by the increased presentation of RANKL on the surface of bone marrow stromal cells (aswell as B andT cells) in postmenopausal compared to premenopausal women and its decreased presentation on these cells in estrogen-treated versus untreated postmenopausal women (Eghbali-Fato…”
BackgroundTreatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies
Chang, B., Quan, Q., Li, Y., Qiu, H., Jiang, P., & Gu, Y. (2018) · Medical Science Monitor · doi:10.12659/msm.912309 · Cited by 25
Fernández‐García, D., Muñoz‐Torres, M., Mezquita‐Raya, P., de la Higuera, M., Alonso, G., Reyes‐García, R., Ochoa, A. S., Ruiz-Requena, M. E., Luna, J. D. D., & Escobar‐Jiménez, F. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346385 · Cited by 26
PRABHAKARAN, K., Harris, E. B., & Kirchheimer, W. F. (1972) · PubMed · Cited by 25
Chang, W., Tian, B., Qin, Q., Li, D., Zhang, Y., Zhou, C., Wu, B., Zhang, M., Shan, H., Ni, Y., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c12064 · Cited by 23
How to Overcome Anabolic Resistance in Dialysis-Treated Patients?
Garibotto, G., Saio, M., Aimasso, F., Russo, E., Picciotto, D., Viazzi, F. C., Verzola, D., Laudon, A., Esposito, P. B., & Brunori, G. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.701386 · Cited by 25
“These findings suggest that RANKL decreases, while its inhibition improves, muscle strength and insulin sensitivity both in osteoporotic mice and humans.”
BackgroundInfluentialMochizuki, T., Yano, K., Ikari, K., & Okazaki, K. (2021) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2021.08.001 · Cited by 25
“Publishing services by Elsev to human RANKL, leading to diminished survival and activation of osteoclasts for bone resorption inhibition [8,9].”
BackgroundApplications of Calcium-Based Nanomaterials in Osteoporosis Treatment
Deng, Y., Wei, W., & Tang, P. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c01306 · Cited by 25
Metadata
- Authors
- Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L.
- Affiliations
- Mayo Clinic (US)
- Amgen (United States) (US)
- Corresponding author
- Riggs, B. Lawrence
- Venue
- Journal of Clinical Investigation
- Published
- 2003-04-15
- Volume
- 111
- Issue
- 8
- Pages
- 1221-1230
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC152939
- OpenAlex
- W4254761345
- Cited by
- 825
- References
- 44
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 28 · 2023: 25 · 2022: 34 · 2021: 36 · 2020: 41 · 2019: 30 · 2018: 39 · 2017: 39 · 2016: 33 · 2015: 45 · 2014: 31 · 2013: 42 · 2012: 52
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- National Institutes of Health (M01-RR00 585, AG 04875, RR-00585)
- U.S. Public Health Service (AG-04875)
- National Institute on Aging (P01-AG04875, P01AG004875)
- National Center for Research Resources (M01-RR00 585, M01RR000585)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- RANK ligand, bone resorption, postmenopausal osteoporosis, estrogen deficiency, osteoclastogenesis, mesenchymal stem cells, T cells, B cells, osteoprotegerin, estradiol, bone turnover markers, paracrine signaling
- MeSH terms
- Adult, Bone Resorption, Carrier Proteins, Female, Flow Cytometry, Glycoproteins, Humans, Membrane Glycoproteins, Middle Aged, Tumor Necrosis Factor-alpha, Osteoporosis, Postmenopausal, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Apoptosis Regulatory Proteins, TNF-Related Apoptosis-Inducing Ligand, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.